Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Retinopati hos for tidligt fødte - visuel funktion og retinal struktur

9. november 2026 opdateret af: Erlend Christoffer Sommer Landsend, Oslo University Hospital

Børn Behandlet for Retinopathia Prematurorum - Undersøgelse af Visuel Funktion og Retinal Struktur

Children born prematurely may develop a characteristic retinal disease named retinopathy of prematurity (ROP). This disease could lead to retinal detachment and blindness. ROP was traditionally treated with laser, but injection with a medication (A-VEGF) has become more common.

In this study, the researchers will explore whether treatment of ROP affects visual function and retinal development. To explore this, the study group will examine children with ROP (but not treated) with children treated with either laser or injection. The researchers will compare the children's visual functions (e.g. visual acuity and visual field) and their retinas (e.g. central and peripheral retina).

Studieoversigt

Detaljeret beskrivelse

Children born prematurely may develop a characteristic retinal disease named retinopathy of prematurity (ROP). The risk of ROP increases with lower gestational age and birth weight of the child. In a child born pre-term the blood vessels in the retina may not be fully developed. New - but unstructured - vessels could grow up from the retina and lead to retinal detachment and blindness. ROP was traditionally treated with laser, but injection with a medication (A-VEGF) into the eye has become more common.

In this study, the researchers aim to explore whether treatment of ROP affects visual function and retinal development. To investigate this, the study group will examine children with ROP (but not treated) with children treated with either laser or injection. The researchers will compare the children's visual functions (e.g. visual acuity and visual field) and their retinas (e.g. central and peripheral retina).

The participants will undergo a comprehensive eye examination, including imaging of the retina, visual field testing, and biometric measurements. Their parents will also answer questions regarding cerebral visual impairment.

Results from the group not treated for ROP will be compared to the treated subjects. Data will also be correlated with non-ocular parameters, such at gestational age, birth weight and brain hemorrhages.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

140

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Erlend Christoffer Sommer Landsend, M.D., Ph.D.
  • Telefonnummer: 0047 91 50 27 70
  • E-mail: erllan@ous-hf.no

Undersøgelse Kontakt Backup

  • Navn: Amanda Schjetlein, M.D.
  • Telefonnummer: 0047 91 50 27 70
  • E-mail: amasch@ous-hf.no

Studiesteder

    • Oslo
      • Oslo, Oslo, Norge, 0424
        • Oslo University Hospital
        • Kontakt:
          • Amanda Schjetlein, M.D.
          • Telefonnummer: 0047 91 50 27 70
          • E-mail: amasch@ous-hf.no
        • Kontakt:
          • Erlend C. S. Landsend, M.D., Ph.D.
          • Telefonnummer: 0047 91 50 27 70
          • E-mail: erllan@ous-hf.no

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

6 år til 20 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

  • Group 1: patients treated for ROP with laser
  • Group 2: patients previously diagnosed with ROP but not treated (matched 1:1 with patients in group 1)
  • Group 3: patients treated for ROP with injection of A-VEGF
  • Group 4: patients previously diagnosed with ROP but not treated (matched 1:1 with patients in group 3)

Beskrivelse

Inclusion criteria:

  • Patients treated for ROP with either laser or injection of A-VEGF.
  • Patients previously diagnosed with ROP but not treated for the condition.

Exclusion criteria:

  • Age below six years at date of examination.
  • A developmental level not compatible with performing the study examinations.
  • Patients born or treated outside Norway
  • Known ocular or systemic disease that can give structural or functional changes in the retina.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: CASE_CONTROL
  • Tidsperspektiver: CROSS_SECTIONAL

Kohorter og interventioner

Gruppe / kohorte
Laser treated

Subjects treated for ROP with laser of avascular retina

Control laser treated

Control subjects matched with subjects treated with laser

A-VEGF treated

Subjects treated for ROP with intravitreal injection of A-VEGF

Control A-VEGF treated

Control subjects matched with subjects treated with A-VEGF

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Width of the foveal avascular zone
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years

Width of the foveal avascular zone in micrometers measured with optical coherence tomography angiography

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years
Choroidal vascularity
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Choroidal vascularity in the macula measured with optical coherence tomography and with choroidal vascularity index in percent

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.
Retinal nerve fiber layer thickness
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Retinal nerve fiber layer thickness in micrometers measured with optical coherence tomography

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.
Length of persistent avascular retina
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Length of persistent avascular retina measured in millimeters using scanning laser ophthalmoscopy and fluorescein angiography

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.
Width of the visual field
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Width of the visual field in degrees measured with Goldmann Perimetry

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Correlation between cerebral visual impairment and brain hemorrhages
Tidsramme: Neonatal period to time for data collection in the current study

Correlation between scores for cerebral visual impairment at time of the study and brain hemorrhages in neonatal period

Neonatal period to time for data collection in the current study
Visual acuity
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Visual acuity measured with LogMAR.

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studiestol: Erlend Christoffer Sommer Landsend, M.D., Ph.D., Oslo University Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

1. januar 2028

Studieafslutning (Anslået)

1. juni 2029

Datoer for studieregistrering

Først indsendt

19. januar 2026

Først indsendt, der opfyldte QC-kriterier

16. februar 2026

Først opslået (Faktiske)

23. februar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. februar 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

IPD-planbeskrivelse

Awaits allowance to share IPD from the Regional committees for medical and health research ethics.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner